Shamburg News · 8-K filed Nov 12, 2026, 4:05 PM EST
BioStem Technologies Reports Q3 2026 Results and Raises Full-Year 2026 Revenue Guidance
BSEM · BioStem Technologies, Inc.
- Earnings
- Materiality: high
BioStem Technologies reported third quarter 2026 net revenue of $7.6 million and a GAAP net loss of $11.4 million, or $0.64 per share, for the quarter ended September 30, 2026. Hospital revenue increased sequentially to $6.8 million. The company raised its full-year 2026 revenue guidance to $28 million to $29 million from $26 million to $29 million, and reported cash and cash equivalents of $1.0 million as of September 30, 2026.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458305.
Written from the filing by Shamburg Markets. Figures are as reported by the company.